Page 38 - 2020_09-Haematologica-web

J. Delgado et al.
Leukemia. 2017;31(1):170-176.
83. Winkelmann N, Rose-Zerilli M, Forster J, et
al. Low frequency mutations independently predict poor treatment-free survival in early stage chronic lymphocytic leukemia and monoclonal B-cell lymphocytosis. Haematologica. 2015;100(6):e237-e239.
The chronic lymphocytic leukemia interna- tional prognostic index predicts time to first treatment in early CLL: Independent valida- tion in a prospective cohort of early stage patients. Am J Hematol. 2016;91(11):1090- 1095.
100.Gentile M, Shanafelt TD, Rossi D, et al. Validation of the CLL-IPI and comparison with the MDACC prognostic index in newly diagnosed patients. Blood. 2016;128(16):2093-2095.
ab versus chlorambucil and obinutuzmab for treatment-naive chronic lymphocytic leukaemia (ELEVATE TN): a randomised, controlled, phase 3 trial. Lancet. 2020;395(10232):1278-1291.
115.Byrd JC, Furman RR, Coutre SE, et al. Targeting BTK with ibrutinib in relapsed chronic lymphocytic leukemia. N Engl J Med. 2013;369(1):32-42.
116.Farooqui MZH, Valdez J, Martyr S, et al. Ibrutinib for previously untreated and relapsed or refractory chronic lymphocytic leukaemia with TP53 aberrations: a phase 2, single-arm trial. Lancet Oncol. 2015;16(2): 169-176.
117.O’Brien S, Jones JA, Coutre SE, et al. Ibrutinib for patients with relapsed or refrac- tory chronic lymphocytic leukaemia with 17p deletion (RESONATE-17): a phase 2, open-label, multicentre study. Lancet Oncol. 2016;17(10):1409-1418.
118. Byrd JC, Brown JR, O’Brien S, et al. Ibrutinib versus ofatumumab in previously treated chronic lymphoid leukemia. N Engl J Med. 2014;371(3):213-223.
119.Chanan-Khan A, Cramer P, Demirkan F, et al. Ibrutinib combined with bendamustine and rituximab compared with placebo, ben- damustine, and rituximab for previously treated chronic lymphocytic leukaemia or small lymphocytic lymphoma (HELIOS): a randomised, double-blind, phase 3 study. Lancet Oncol. 2016;17(2):200-211.
120.Roberts AW, Davids MS, Pagel JM, et al. Targeting BCL2 with venetoclax in relapsed chronic lymphocytic leukemia. N Engl J Med. 2016;374(4):311-322.
121. Stilgenbauer S, Eichhorst B, Schetelig J, et al. Venetoclax in relapsed or refractory chronic lymphocytic leukaemia with 17p deletion: a multicentre, open-label, phase 2 study. Lancet Oncol. 2016;17(6):768-778.
122. Jones JA, Mato AR, Wierda WG, et al. Venetoclax for chronic lymphocytic leukaemia progressing after ibrutinib: an interim analysis of a multicentre, open-label, phase 2 trial. Lancet Oncol. 2018;19(1):65-75.
123.Coutre S, Choi M, Furman RR, et al. Venetoclax for patients with chronic lym- phocytic leukemia who progressed during or after idelalisib therapy. Blood. 2018;131(15):1704-1711.
124. Seymour JF, Kipps TJ, Eichhorst B, et al. Venetoclax-rituximab in relapsed or refrac- tory chronic lymphocytic leukemia. N Engl J Med. 2018;378(12):1107-1120.
125. Furman RR, Sharman JP, Coutre SE, et al. Idelalisib and rituximab in relapsed chronic lymphocytic leukemia. N Engl J Med. 2014;370(11):997-1007.
126.Sharman JP, Coutre SE, Furman RR, et al. Final results of a randomized, phase III study of rituximab with or without idelalisib fol- lowed by open-label idelalisib in patients with relapsed chronic lymphocytic leukemia. J Clin Oncol. 2019;37(16):1391- 1402.
127. Kreuzer KA, Furman RR, Stilgenbauer S, et al. The impact of complex karyotype on the overall survival of patients with relapsed chronic lymphocytic leukemia treated with idelalisib plus rituximab. Leukemia. 2020;34(1):296-300.
128.Anderson MA, Tam C, Lew TE, et al. Clinicopathological features and outcomes of progression of CLL on the BCL2 inhibitor venetoclax. Blood. 2017;129(25):3362-3370.
129. Maddocks KJ, Ruppert AS, Lozanski G, et al. Etiology of ibrutinib therapy discontinua- tion and outcomes in patients with chronic lymphocytic leukemia. JAMA. Oncol
84.Gruber M, Bozic I, Leshchiner I, et al. Growth dynamics in naturally progressing chronic lymphocytic leukaemia. Nature. 2019;570(7762):474-479.
85. Montserrat E, Sanchez‐Bisono J, Viñolas N, Rozman C. Lymphocyte doubling time in chronic lymphocytic leukaemia: analysis of its prognostic significance. Br J Haematol. 1986;62(3):567-575.
101.
Delgado J, Doubek M, Baumann T, et al. Chronic lymphocytic leukemia: a prognostic model comprising only two biomarkers (IGHV mutational status and FISH cytoge- netics) separates patients with different out- come and simplifies the CLL-IPI. Am J Hematol. 2017;92(4):375-380.
86. Hallek M, Cheson BD, Catovsky D, et al. iwCLL guidelines for diagnosis, indications for treatment, response assessment, and supportive management of CLL. Blood. 2018;131(25):2745-2760.
87.Al-Sawaf O, Robrecht S, Bahlo J, et al. Richter transformation in chronic lympho- cytic leukemia (CLL)—a pooled analysis of German CLL Study Group (GCLLSG) front line treatment trials. Leukemia. 2020 Mar 17. [Epub ahead of print].
88. Fabbri G, Khiabanian H, Holmes AB, et al. Genetic lesions associated with chronic lym- phocytic leukemia transformation to Richter syndrome. J Exp Med. 2013;210(11):2273- 2288.
89. Kadri S, Lee J, Fitzpatrick C, et al. Clonal evolution underlying leukemia progression and Richter transformation in patients with ibrutinib-relapsed CLL. Blood Adv. 2017;1(12):715-727.
90. Miller CR, Ruppert AS, Heerema NA, et al. Near-tetraploidy is associated with Richter transformation in chronic lymphocytic leukemia patients receiving ibrutinib. Blood Adv. 2017;1(19):1584-1588.
91. Kwok M, Oldreive C, Rawstron AC, et al. Integrative analysis of spontaneous CLL regression highlights genetic and microenvi- ronmental interdependency in CLL. Blood. 2020;135(6):411-428.
92. Rai KR, Sawitsky A, Cronkite EP, Chanana AD, Levy RN, Pasternack BS. Clinical stag- ing of chronic lymphocytic leukemia. Blood. 1975;46(2):219-234.
93. Binet JL, Auquier A, Dighiero G, et al. A new prognostic classification of chronic lympho- cytic leukemia derived from a multivariate survival analysis. Cancer. 1981;48(1):198- 206.
94. Baliakas P, Hadzidimitriou A, Sutton L-A, et al. Recurrent mutations refine prognosis in chronic lymphocytic leukemia. Leukemia. 2015;29(2):329-336.
95.Rossi D, Rasi S, Spina V, et al. Integrated mutational and cytogenetic analysis identi- fies new prognostic subgroups in chronic lymphocytic leukemia. Blood. 2013;121(8): 1403-1412.
96. Baliakas P, Moysiadis T, Hadzidimitriou A, et al. Tailored approaches grounded on immunogenetic features for refined prog- nostication in chronic lymphocytic leukemia. Haematologica. 2019;104(2):360- 369.
97. International CLL-IPI working groups. An international prognostic index for patients with chronic lymphocytic leukaemia (CLL- IPI): a meta-analysis of individual patient data. Lancet Oncol. 2016;17(6):779-790.
98. da Cunha-Bang C, Christiansen I, Niemann CU. The CLL-IPI applied in a population- based cohort. Blood. 2016;128(17):2181- 2183.
99. Molica S, Shanafelt TD, Giannarelli D, et al.
102. Condoluci A, Terzi di Bergamo L, Langerbeins P, et al. International prognostic score for asymptomatic early-stage chronic lymphocytic leukemia. Blood. 2020;135(21): 1859-1869.
103.Dighiero G, Maloum K, Desablens B, et al. Chlorambucil in indolent chronic lympho- cytic leukemia. French Cooperative Group on Chronic Lymphocytic Leukemia. N Engl J Med. 1998;338(21):1506-1514.
104.Herling CD, Cymbalista F, Groß-Ophoff- Müller C, et al. Early treatment with FCR versus watch and wait in patients with stage Binet A high-risk chronic lymphocytic leukemia (CLL): a randomized phase 3 trial. Leukemia. 2020 Feb 18. [Epub ahead of print].
105.Langerbeins P, Bahlo J, Rhein C, et al. Ibrutinib versus placebo in patients with asymptomatic treatment-naïve early stage CLL: primary endpoint results of the phase 3 double-blind randomized CLL12 trial. Hematol Oncol. 2019;37(Suppl 2):38-40.
106.Burger JA, Tedeschi A, Barr PM, et al. Ibrutinib as initial therapy for patients with chronic lymphocytic leukemia. N Engl J Med. 2015;373(25):2425-2437.
107. Shanafelt TD, Wang X V., Kay NE, et al. Ibrutinib–rituximab or chemoimmunothera- py for chronic lymphocytic leukemia. N Engl J Med. 2019;381(5):432-443.
108. Woyach JA, Ruppert AS, Heerema NA, et al. Ibrutinib regimens versus chemoim- munotherapy in older patients with untreat- ed CLL. N Engl J Med. 2018;379(26):2517- 2528.
109.Moreno C, Greil R, Demirkan F, et al. Ibrutinib plus obinutuzumab versus chlo- rambucil plus obinutuzumab in first-line treatment of chronic lymphocytic leukaemia (iLLUMINATE): a multicentre, randomised, open-label, phase 3 trial. Lancet Oncol. 2019;20(1):43-56.
110.
Burger JA, Sivina M, Jain N, et al. Randomized trial of ibrutinib vs ibrutinib plus rituximab in patients with chronic lym- phocytic leukemia. Blood. 2019;133(10): 1011-1019.
111.Diop F, Moia R, Favini C, et al. Biological and clinical implications of BIRC3 mutations in chronic lymphocytic leukemia. Haematologica. 2020;105(2):448-456.
112.Tausch E, Schneider C, Robrecht S, et al. Prognostic and predictive impact of genetic markers in patients with CLL treated with obinutuzumab and venetoclax. Blood. 2020 Mar 23. [Epub ahead of print].
113.Fischer K, Al-Sawaf O, Bahlo J, et al. Venetoclax and obinutuzumab in patients with CLL and coexisting conditions. N Engl J Med. 2019;380(23):2225-2236.
114.Sharman JP, Egyed M, Jurczak W, et al. Acalabrutinib with or without obinutuzum-
2216
haematologica | 2020; 105(9)